Cybrexa Therapeutics
Business Services · Connecticut, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
395 Winchester Ave, New Haven, Connectic...Phone Number
(860) 717-2731Website
www.cybrexa.comRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Cybrexa Therapeutics
Cybrexa Therapeutics is a biotechnology company dedicated to developing a new class of tumor-targeted cancer therapies. The company is headquartered in New Haven, Connecticut.Explore more
Cybrexa Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cybrexa Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Cybrexa Therapeutics
Funding: Get notified immidiatlly once Cybrexa Therapeutics has new funding data
Check out if Cybrexa Therapeutics is spiking on competitors!
Product Launch: Get notified when Cybrexa Therapeutics launches new products
Earning: See what the market has to say on Cybrexa Therapeutics recently announced quarterly report
Check if Cybrexa Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Cybrexa Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Cybrexa Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Cybrexa Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Cybrexa Therapeutics
Compare insights from companies similar to Cybrexa Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cybrexa Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cybrexa Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cybrexa Therapeutics.
Cybrexa Therapeutics financials insights
Gather financial insights about Cybrexa Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
2021
Series B
$25M
Cybrexa Therapeutics Tech Stack
A closer look at the technologies used by Cybrexa Therapeutics
Most Recent Scoops
Project
Product Development, Product Management, Medical Research, Pharmaceuticals, Clinical Operations
Left Company
Executive Move
New Hire
Executive Move
Lateral Move
New Hire
Executive Move
Cybrexa Therapeutics News & Media
Latest Updates of Viva Biotech's Portfolio Companies
HONG KONG, Oct. 30, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization. Recently, Viva Biotech's portfolio companies have new updates. Keep reading for more details. Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement IsletsCybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer
Cybrexa announces the first patient has been dosed in a Ph2 clinical trial evaluating CBX-12 in women with platinum-resistant or refractory ovarian cancer.Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid TumorsIndustry Leader John Maraganore, Ph.D., Joins Cybrexa Therapeutics as Strategic Advisor
NEW HAVEN, Conn., June 25, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC) therapeutics, today announced that John Maraganore, Ph.D., has joined as a Strategic Advisor to the Company’s Executive Leadership Team. In this role, Dr. Maraganore will provide strategic guidance and leverage his extensive experience in the biotech industry to support the advancement of our alphalex™ t
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Cybrexa Therapeutics
Sign Up For FreeTo access detailed company insights
Cybrexa Therapeutics is a biotechnology company dedicated to developing a new class of tumor-targeted cancer therapies. The company is headquartered in New Haven, Connecticut.... Read More
